Page 99 - Read Online

Ma et al. J Cancer Metastasis Treat 2022;8:25 https://dx.doi.org/10.20517/2394-4722.2022.17 Page 17 of 20

lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Am J Hematol 2019;94:641-9. DOI PubMed PMC
9. Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:1011-9. DOI PubMed PMC
10. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary
syndrome. Blood 2009;113:127-36. DOI PubMed
11. Dunn J, McCuaig R, Tu WJ, Hardy K, Rao S. Multi-layered epigenetic mechanisms contribute to transcriptional memory in T
lymphocytes. BMC Immunol 2015;16:27. DOI PubMed PMC
12. Antignano F, Zaph C. Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation. Immunol Cell
Biol 2015;93:245-52. DOI PubMed
13. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell
lymphoma. Blood 2014;123:2915-23. DOI PubMed PMC
14. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T
cell lymphomas. Nat Genet 2014;46:166-70. DOI PubMed PMC
15. Ji MM, Huang YH, Huang JY, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Haematologica 2018;103:679-87. DOI
16. Sandell RF, Boddicker RL, Feldman AL. Genetic landscape and classification of peripheral T Cell lymphomas. Curr Oncol Rep
2017;19:28. DOI PubMed PMC
17. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a
recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38. DOI PubMed
18. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N
Engl J Med 2014;371:2477-87. DOI PubMed PMC
19. Bowman RL, Levine RL. TET2 in normal and malignant hematopoiesis. Cold Spring Harb Perspect Med 2017;7:a026518. DOI
PubMed PMC
20. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012;366:95-6. DOI
PubMed
21. Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like
features and adverse clinical parameters. Blood 2012;120:1466-9. DOI PubMed
22. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood
2014;123:1293-6. DOI PubMed PMC
23. Muto T, Sashida G, Hasegawa N, et al. Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2
in mice. Leuk Lymphoma 2015;56:520-3. DOI PubMed
24. Ichiyama K, Chen T, Wang X, et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine
gene expression in T cells. Immunity 2015;42:613-26. DOI PubMed PMC
25. Cortés JR, Palomero T. Biology and molecular pathogenesis of mature T-Cell lymphomas. Cold Spring Harb Perspect Med
2021;11:a035402. DOI PubMed PMC
26. Scourzic L, Couronné L, Pedersen MT, et al. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA
methylation control to induce lymphoid malignancies in mice. Leukemia 2016;30:1388-98. DOI PubMed PMC
27. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012;119:1901-
3. DOI PubMed PMC
28. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme
activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34. DOI PubMed PMC
29. Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell
lymphoma. Blood 2015;126:1741-52. DOI PubMed PMC
30. Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc 2013;251:242-9. DOI PubMed
31. Jaffe AB, Aspenström P, Hall A. Human CNK1 acts as a scaffold protein, linking Rho and Ras signal transduction pathways. Mol
Cell Biol 2004;24:1736-46. DOI PubMed PMC
32. Morin P, Flors C, Olson MF. Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and
impairing cytokinesis. Eur J Cell Biol 2009;88:495-507. DOI PubMed PMC
33. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet
2014;46:171-5. DOI PubMed
34. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat
Genet 2014;46:371-5. DOI PubMed
35. Ng SY, Brown L, Stevenson K, et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in
mice. Blood 2018;132:935-47. DOI PubMed
36. Cortes JR, Ambesi-Impiombato A, Couronné L, et al. RHOA G17V induces T follicular helper cell specification and promotes
lymphomagenesis. Cancer Cell 2018;33:259-273.e7. DOI PubMed PMC
37. Zang S, Li J, Yang H, et al. Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. J Clin
Invest 2017;127:2998-3012. DOI PubMed PMC
38. Boddicker RL, Razidlo GL, Dasari S, et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in